marcus

Testolone is a promising new anabolic agent that inhibits growth of breast cancer AR/ER+ cells by reducing the gene ESR1. Its tissue-selective AR activity, oral availability, and overall acceptance in animal models makes it an attractive candidate for clinical investigation for patients. However, prior to considering its use, it is important to be aware that … Read more

Testolone is a promising new anabolic agent that blocks the growth of breast cancer AR/ER+ cells by reducing the gene ESR1. Its tissue-selective AR activity and its oral availability make it a promising candidate to conduct clinical research in patients. But, before considering its application, it is important to know that this substance is not … Read more

Testolone is a promising new anabolic compound that inhibits growth of breast cancer AR/ER+ cells by suppressing the gene ESR1. Its tissue-selective AR activity, oral availability, and general acceptance in animal models makes it a desirable candidate for clinical studies for patients. But, before considering its application, it is important to know that this substance … Read more

RAD 140, a promising new anabolic medication, inhibits the growth of AR/ER+ breast carcinoma cells by suppressing ESR1. Its tissue-specific AR activity and its oral availability makes it a great candidate for clinical research on patients. It is important to keep in mind that professional athletes are not permitted to take this drug therefore it … Read more

Testolone is a promising new anabolic agent that blocks the growth of AR/ER+ breast cancer cells by reducing the gene ESR1. Its tissue-specific AR activity and oral accessibility, as well as overall tolerability in animal models make it a promising possibility for clinical study for patients. It is important to remember that professional athletes are … Read more

Testolone is a promising new anabolic agent that blocks growth of breast cancer AR/ER+ cells by suppressing the gene ESR1. Its tissue-selective AR activity and oral accessibility, as well as general acceptance in animal models makes it a compelling possibility for clinical study in patients. It is crucial to remember that professional athletes are not … Read more

Testolone is a promising new anabolic agent that blocks the growth of breast cancer AR/ER+ cells by suppressing the gene ESR1. Its tissue-specific AR activity as well as its oral availability and overall tolerability in animal models make it a compelling candidate for clinical investigation in patients. However, before considering its use, it is important … Read more

RAD 140, a promising new anabolic drug, blocks the growth of AR/ER+ breast carcinoma cells by suppressing ESR1. Its tissue-specific AR activity and oral accessibility makes it a viable candidate for clinical research with patients. However, prior to considering its use, it is crucial to know that this substance is not approved for use by … Read more

RAD 140, a promising new anabolic medication, inhibits the growth of AR/ER+ breast cancer cells by reducing ESR1. Its tissue-specific AR activity, oral availability, and general tolerance in animal models make it a desirable candidate for clinical investigation for patients. But, before considering its use, it’s important to note that this substance is not approved … Read more

Testolone is a promising new anabolic agent that blocks the growth of breast cancer AR/ER+ cells by suppressing the gene ESR1. Its tissue-specific AR activity as well as its oral availability and general acceptance in animal models makes it a desirable candidate for clinical investigation for patients. But, before considering its use, it is crucial … Read more